HARTE-HANKS INC

Harte‑Hanks shares dip 6.6% amid U.S. peptide policy shifts, yet its robust trading volume and commitment to quality may unlock new market opportunities.

Harte‑Hanks faces a sharp decline amid new leadership and a push for data‑driven digital transformation—can a technology‑first pivot reverse its slide?

Harte‑Hanks (HHS) shares climb 1.63% to $4.20, trading above the 200‑day SMA, as investors weigh modest volume and peer gains for a potential rebound.